Kenneth K. Iwata - Concepedia

Author

Kenneth K. Iwata

Also Known As

K Iwata, K K Iwata, K. Iwata, K. K. Iwata, K.K. Iwata, KENNETH K. IWATA, Katsuya Iwata, Kenneth Iwata, Kenneth K Iwata, Kenneth K. Iwata

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)National Cancer Institute The University of Texas Health Science Center at San Antonio Rockefeller University North Shore University Hospital

About

Kenneth K. Iwata is an author at Pfizer (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	22	2.3K
2	Natural Sciences	3	3	380
3	Health Sciences	2	2	68
4	Biochemistry	1	1	30
5	Biology	1	1	45

Kenneth K. Iwata

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Epithelial to Mesenchymal Transition Is a Determinant of Sensitivity of Non–Small-Cell Lung Carcinoma Cell Lines and Xenografts to Epidermal Growth Factor Receptor Inhibition Stuart Thomson, Elizabeth Buck, Filippo Petti, Cancer Research	2005	669
Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358,774: Dynamics of Receptor Inhibition In Situ and Antitumor Effects in Athymic Mice Vincent A. Pollack, Douglas M. Savage, Deborah A. Baker, Journal of Pharmacology and Experimental Therapeutics	1999	430
Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms Sela Cheifetz, Humberto Hernandez, Marikki Laiho, Journal of Biological Chemistry Cellular ResponsivenessHuman GrowthImmunologyCell GrowthCellular Physiology	1990	357
Identification of another member of the transforming growth factor type beta gene family. Peter ten Dijke, Pamela F. Hansen, Kenneth K. Iwata, Proceedings of the National Academy of Sciences Human GrowthGeneticsMolecular BiologyMolecular GeneticsProtein Synthesis	1988	326
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non–small-cell lung, pancreatic, colon, and breast tumors Elizabeth Buck, Alexandra Eyzaguirre, Eric Brown, Molecular Cancer Therapeutics Tumor BiologyEpidermal Growth FactorNon–small-cell LungGastrointestinal OncologyMedicine	2006	233
Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors Elizabeth Buck, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Cancer Research Small Molecule InhibitorsTumor BiologyReceptor Tyrosine KinaseGrowth InhibitionCell Signaling	2008	209
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition Elizabeth Buck, Alexandra Eyzaguirre, Sharon Barr, Molecular Cancer Therapeutics	2007	188
Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer Milind Javle, John F. Gibbs, Kenneth K. Iwata, Annals of Surgical Oncology Epithelial-mesenchymal TransitionTumor BiologySurgical OncologyOncologyPancreatic Cancer	2007	152
Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor beta 3. Stephen T. Sonis, Loryn E. Lindquist, A. Van Vugt, PubMed InflammationOral MucosaGastrointestinal PharmacologyGrowth FactorMedicine	1994	148
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity Elizabeth Buck, Alexandra Eyzaguirre, John D. Haley, Molecular Cancer Therapeutics Pancreatic CancerMedicineReceptor Tyrosine KinaseErlotinib-sensitive Cell LinesPathology	2006	114

Page 1